The scientific complexity and economic cost of developing new cancer therapies demand a level of collaboration and sharing that takes both industry and academia well beyond their comfort zones. EORTC head Denis Lacombe believes he [more]
The side effects of targeted drugs are poorly documented, and their impact on patients frequently seriously underestimated and undertreated. Efforts to address these issues could improve survival as well as quality of life. The image [more]
EORTC boosts efforts to address the long-term problems faced by people who have been treated for cancer. The number of people who are living long lives after cancer treatment has been rising year on year, [more]